TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02816762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Conventional anti-diabetic diet recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Conventional anti-diabetic diet recommendations
Study: NCT00088010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arzoxifene
Description: 20mg, oral, tablet, once a day for 36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, tablet, once a day for 36 months
Study: NCT02269618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care All patients will be followed also in usual care manner by their GPs.
Study: NCT00729118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Study: NCT02269618

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care All patients will be followed also in usual care manner by their GPs.
Study: NCT03548545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
Study: NCT01861756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice decision aid
Description: The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
Study: NCT01375712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented milk containing Lactobacillus casei strain Shirota
Description: A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of Lactobacillus casei strain Shirota.
Study: NCT03081325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-dose lymphocyte immunotherapy
Description: Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
Study: NCT02961647

Intervention type: PROCEDURE
Intervention: Mitral valve repair
Description: The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
Study: NCT01375712

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
Study: NCT03650738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
Study: NCT03757611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tabetri capsule
Description: 1,000 mg/capsule (Taheebo extract 600 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 1,000 mg/capsule
Study: NCT03430128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMPACT immunotherapy
Description: Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ENSURE
Description: Liquid milk formula available over the counter
Study: NCT04450433

Intervention type: DIAGNOSTIC_TEST
Intervention: aortic dissection and healthy people
Description: Differential expression of metabolites in patients with aortic dissection and healthy people

Intervention type: DIAGNOSTIC_TEST
Intervention: aortic dissection and healthy people
Description: Differential expression of metabolites in patients with aortic dissection and healthy people

Intervention type: DIAGNOSTIC_TEST
Intervention: aortic dissection and healthy people
Description: Differential expression of metabolites in patients with aortic dissection and healthy people
Study: NCT02674607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Study: NCT01315015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast enhanced breast MRI
Description: Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
Study: NCT00443404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative epidural catheter
Description: Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative epidural catheter
Description: Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative epidural catheter
Description: Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
Study: NCT02834715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia rebaudiana liquid extract
Description: Sweetener made of liquid stevia self administered daily for 30 days
Study: NCT00443404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative epidural catheter
Description: Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perioperative epidural catheter
Description: Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
Study: NCT04142476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interview
Description: interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
Study: NCT02157831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-870,893
Study: NCT03792750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified Dose on Specified Day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Day
Study: NCT00931957

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept, Methotrexate, Prednisolone
Description: In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept, Methotrexate, Prednisolone
Description: In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.
Study: NCT03645486

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of lentiviral TYF-CGD-modified autologous stem cells
Description: Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight
Study: NCT01139723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINT1526A
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINT1526A
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study: NCT03102775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive follow-up program for low-income families
Description: The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local family projects
Description: The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
Study: NCT04195750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Oral tablets
Study: NCT03920852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 1.5% cream applied twice daily.
Study: NCT03856073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novice
Description: Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
Study: NCT00830453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Description: 60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
Study: NCT00266110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
Study: NCT01394029

Intervention type: DRUG
Intervention: deferasirox
Study: NCT01555463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam, 15% (BAY39-6251)
Description: Azelaic acid twice daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: twice daily topical application
Study: NCT03611309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgeon-palliative care team co management
Description: Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team

Intervention type: OTHER
Group type: OTHER
Intervention: Surgeon team alone management
Description: The surgeon and surgical team will manage
Study: NCT01775488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vortx Rx - Histotripsy BPH Device
Description: Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
Study: NCT02091622

Intervention type: OTHER
Group type: OTHER
Intervention: Educative intervention
Description: Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
Study: NCT01675921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook group
Description: Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
Study: NCT02016157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
Study: NCT04561843

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic floor ultrasound
Description: 2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic floor ultrasound
Description: 2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
Study: NCT05480137

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NSE scoring balloon and plain balloon angioplasty
Description: Using NSE scoring balloon or plain balloon in BPA surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NSE scoring balloon and plain balloon angioplasty
Description: Using NSE scoring balloon or plain balloon in BPA surgery.
Study: NCT02369458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT03518229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microsoft Band 2 + UV messaging
Description: wearable device (wrist) and associated mobile application; UV sensor and messaging activated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microsoft Band 2
Description: wearable device (wrist) and associated mobile application; UV messaging not activated
Study: NCT01176396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries prevention active intervention
Description: Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control treatment
Description: Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding).
Study: NCT02272621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement
Study: NCT02369458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT02272621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full sternotomy aortic valve replacement
Study: NCT00268762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: argatroban
Description: Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
Study: NCT03621046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03972696

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
Study: NCT02844075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475(pembrolizumab)
Description: Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery.